Stay informed about the latest developments in our mission to bring MOTYS™ to patients with osteoarthritis.
Doron Therapeutics has initiated its Phase 3 clinical trial for MOTYS (PTP-001), dosing the first patients in a global study aimed at evaluating the efficacy of this injectable biologic therapy for knee osteoarthritis. This milestone marks a significant step forward in bringing this innovative treatment to patients...
Read full article
Doron Therapeutics has completed a successful End-of-Phase 2 and initial RMAT meeting with the FDA, confirming the Phase 3 clinical program's design and scope for MOTYS in treating knee osteoarthritis. This productive dialogue with the FDA provides clear guidance for our pivotal trials...
Read full article
The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to MOTYS, Doron Therapeutics' lead placental tissue-derived biologic, recognizing its potential to address unmet medical needs in knee osteoarthritis treatment. This designation provides expedited development and review opportunities...
Read full article
Doron Therapeutics has successfully raised $11 million in a Series A funding round led by SPRIM Global Investments, aiming to advance MOTYS into Phase 3 clinical studies for symptomatic knee osteoarthritis. This investment strengthens our financial position and accelerates our path to bringing MOTYS to market...
Read full articleDiscover the science behind our breakthrough therapy for osteoarthritis.